Asset profile
picankibart
Monoclonal antibody
Evidence outlook · lead readout
NCT06049810 · Psoriasis
The completed lead evidence has the design features that historically survive confirmatory trials: randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.
NCT06049810: After an initial response to picankibart, patients were randomized and blinded to either continue active treatment or switch to placebo; a hard, disease-defining skin-severity measure (PASI90) at Week 56 showed continued picankibart maintained response in about 90% of patients versus 38-52% after withdrawal to placebo (P<0.0001 for both comparisons).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Also in development:Ulcerative Colitis · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
129 competitors in this universe: 14 direct rivals (same mechanism and indication), 0 same-class, 115 same-indication; 73 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Picankibart: this drug | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| Guselkumab (Tremfya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Mirikizumab (Omvoh) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Risankizumab (Skyrizi) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Tildrakizumab (Ilumya) | Approved | Monoclonal antibody | IL-23 p19 | ||
| Ustekinumab-Stba (Steqeyma) | Approved | — | IL-23 p19, IL-12 p40 | ||
| Ustekinumab-Ttwe (Pyzchiva) | Approved | — | IL-23 p19, IL-12 p40 | ||
| HS-20137 | Phase 3 | Monoclonal antibody | IL-23 p19 | ||
| JNJ-78934804 | Phase 3 | Combination | IL-23 p19, TNF-alpha | ||
| MT-201 | Phase 2 | Multispecific antibody | TL1A, IL-23 p19 | ||
| ORKA-001 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| SHR-1139 | Phase 2 | Monoclonal antibody | IL-23 p19, IL-36 receptor | ||
| SPY003 | Phase 2 | Monoclonal antibody | IL-23 p19 | ||
| SOR102 | Phase 1 | Biologic (subtype unspecified) | TNF-alpha, IL-23 p19 | ||
| TL-003 | Phase 1 | Multispecific antibody | TL1A, IL-23 p19 | ||
| Adalimumab (Humira) | Approved | Monoclonal antibody | TNF-alpha |
…and 114 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
8 further head-to-head pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.